Get the Stockscreener App
197.93
2.17%
4.21
After Hours:
198.35
0.42
+0.21%
Overview
News
Price History
Option Chain
Financials
Why DHR Down?
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $197.93, with a volume of 3.99M.
It is up +2.17% in the last 24 hours and up +12.39% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$193.72
Open:
$197.47
24h Volume:
3.99M
Relative Volume:
0.88
Market Cap:
$140.09B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
38.25
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
+2.44%
1M Performance:
+12.39%
6M Performance:
-14.09%
1Y Performance:
-2.26%
1-Day Range:
$194.47
$198.23
1-Week Range:
$188.99
$198.23
52-Week Range:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, NTRA, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
197.93 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
523.44 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
557.80 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
279.32 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
WAT
Waters Corp
|
379.29 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Danaher Corp. focuses on diversified science tools as investors weigh long term growth - AD HOC NEWS
Danaher Corp adjusts guidance after Masimo deal. Analysts highlight cautious upside for the stock - AD HOC NEWS
Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS Insider - GlobeNewswire Inc.
DHRDanaher Corp Latest SEC Filings - Finviz
Deals tracker: Select Medical Holdings acquisition moves forward - Modern Healthcare
Danaher Corp. stock underperforms Monday when compared to competitors - MarketWatch
$1M Danaher grant targets Ebola outbreak in Congo, Uganda - Stock Titan
Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation - Insider Monkey
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts? - Insider Monkey
Danaher schedules Q2 earnings call, analysts reassess the shares - Ad-hoc-news.de
Danaher schedules Q2 earnings call, shares steady in S&P 500 - Ad-hoc-news.de
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher boosts product portfolio with the acquisition of Masimo - MSN
Danaher clears new AI milestone with Masimo, shares react on NYSE - Ad-hoc-news.de
Danaher Corp Shs Unsponsored Brazilian Depository Receipt Repr 0.035714285 Sh - TradingView
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DHR Forecast — Price Target — Prediction for 2027 - TradingView
Danaher (DHR) Stock Weighs Mixed Valuation Signals After Recent Price Rebound - Yahoo Finance
Why Danaher (DHR) Stock Rose Today - Quiver Quantitative
Danaher clears FDA hurdle with Masimo, shares extend rebound on NYSE - Ad-hoc-news.de
Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Why Is (NYSE:DHR) Back in Focus Following AI Monitoring Approval? - Kalkine Media
Danaher $172.5 Million Securities Class Action Settlement - Claim Depot
Is Danaher (DHR) Using Masimo’s New FDA-Cleared AI Tool To Redefine Its Medtech Edge? - Yahoo Finance
A Look at Danaher Corp (DHR) After 5.5% Gain -- GF Value $236.97 vs Price $188.87 - GuruFocus
Danaher Corp Stock (DHR) Moved Up by 4.91% on Jun 24: What Investors Need To Know - TradingKey
HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why - Insider Monkey
How FDA Clearance of AI Opioid-Respiratory Monitoring Could Shape Danaher’s (DHR) Clinical Data Advantage - simplywall.st
Danaher achieves FDA clearance for Masimo feature, shares steady on NYSE - Ad-hoc-news.de
Danaher Corp (DHR) Institutional Confidence - TradingKey
Danaher plans July 21 earnings call, slide deck at 6 a.m. ET - Stock Titan
Danaher Finalizes $9.9B Purchase of Masimo - Orange County Business Journal
Danaher (DHR) Achieves FDA Clearance for Wearable Monitoring Tec - GuruFocus
Danaher Schedules Second Quarter 2026 Earnings Conference Call - Yahoo Finance
Danaher Stockweekly outlook with earnings and events ahead - Ad-hoc-news.de
Medtech business update: Spectrum Vascular acquires Piccolo Medical, Danaher acquires Masimo - Today's Medical Developments
From bench chaos to calm order, Cytiva ÄKTA pure quietly cleans up protein prep - AD HOC NEWS
Lodi's largest private employer expands with fifth building - The Business Journals
Danaher Corp (DHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Danaher Corp (DHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Danaher Corp (DHR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Danaher Corp (DHR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Danaher Corp (DHR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Danaher Corp (DHR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Danaher Corp (DHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDBS and Alchemi partner to accelerate biopharma regulatory filings with compliant AI agents - PR Newswire
Danaher’s Cepheid Ebola Tests Highlight Diagnostics Role In Global Crises - Yahoo! Finance Canada
Masimo CEO stepping down following acquisition by Danaher - Modern Healthcare
Danaher Corporation’s (DHR) Recovery Fell Short of Investor Expectations - Yahoo Finance
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
2.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):